Cargando…
Radioimmunotherapy Targeting IGF2R on Canine-Patient-Derived Osteosarcoma Tumors in Mice and Radiation Dosimetry in Canine and Pediatric Models
Background: Osteosarcoma (OS) has an overall patient survival rate of ~70% with no significant improvements in the last two decades, and novel effective treatments are needed. OS in companion dogs is phenotypically close to human OS, which makes a comparative oncology approach to developing new trea...
Autores principales: | Broqueza, Jaline, Prabaharan, Chandra B., Allen, Kevin J. H., Jiao, Rubin, Fisher, Darrell R., Dickinson, Ryan, MacDonald-Dickinson, Valerie, Uppalapati, Maruti, Dadachova, Ekaterina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779382/ https://www.ncbi.nlm.nih.gov/pubmed/35056067 http://dx.doi.org/10.3390/ph15010010 |
Ejemplares similares
-
Novel Human Antibodies to Insulin Growth Factor 2 Receptor (IGF2R) for Radioimmunoimaging and Therapy of Canine and Human Osteosarcoma
por: Broqueza, Jaline, et al.
Publicado: (2021) -
Characterization of IGF2R Molecular Expression in Canine Osteosarcoma as Part of a Novel Comparative Oncology Approach
por: Boisclair, Charles, et al.
Publicado: (2023) -
Image-Based Dosimetry in Dogs and Cross-Reactivity with Human Tissues of IGF2R-Targeting Human Antibody
por: Allen, Kevin J. H., et al.
Publicado: (2023) -
Detection and targeting insulin growth factor receptor type 2 (IGF2R) in osteosarcoma PDX in mouse models and in canine osteosarcoma tumors
por: Karkare, Sharayu, et al.
Publicado: (2019) -
Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium
por: Allen, Kevin J. H., et al.
Publicado: (2019)